Celltrion, Inc.
068270
Clasificación en acciones
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Precio por acción
$146.63
Capitalización bursátil
$33.44B
Cambio (1 día)
-1.52%
Cambio (1 año)
23.60%
País
KR
Comercio Celltrion, Inc. (068270)
Categoría
Healthcare
Margen Operativo de Celltrion, Inc. (068270)
Margen Operativo al October 2026 TTM: 31.56%
Según los informes financieros más recientes y el precio de las acciones de Celltrion, Inc., el margen operativo actual (TTM) es 31.56%. Al final de 2024, el margen operativo era 13.83%.
Historial de Margen Operativo de Celltrion, Inc. desde 2007 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 31.56% | 12.43% |
| 2025 | 28.07% | 102.96% |
| 2024 | 13.83% | -53.79% |
| 2023 | 29.93% | 5.61% |
| 2022 | 28.34% | -27.89% |
| 2021 | 39.30% | 1.13% |
| 2020 | 38.86% | 14.94% |
| 2019 | 33.81% | 2.77% |
| 2018 | 32.90% | -37.50% |
| 2017 | 52.64% | 41.35% |
| 2016 | 37.24% | -13.21% |
| 2015 | 42.91% | 0.33% |
| 2014 | 42.77% | -3.10% |
| 2013 | 44.14% | -20.91% |
| 2012 | 55.81% | -13.15% |
| 2011 | 64.26% | 9.06% |
| 2010 | 58.92% | 19.51% |
| 2009 | 49.30% | 34.08% |
| 2008 | 36.77% | 1,237.09% |
| 2007 | 2.75% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -98.78% |
US
|
|
| -149.01% | -104.72% |
US
|
|
| 25.57% | -99.19% |
AU
|
|
| 31.23% | -99.01% |
BE
|
|
| 28.81% | -99.09% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.